|Bid||52.77 x 800|
|Ask||57.57 x 1000|
|Day's Range||55.05 - 56.69|
|52 Week Range||43.51 - 72.41|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||233.33|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.53|
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive Inc NASDAQ/NGS:NUVAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate Bearish sentimentShort interest | PositiveShort interest is moderate for NUVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NUVA are favorable, with net inflows of $3.46 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SAN DIEGO, March 6, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its participation in and sponsorship of Spine Summit 2019 – 35th Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves, held March 14–17, 2019 at the Fountainebleau Miami Beach. NuVasive will facilitate surgeon education experiences at the summit through participation in a surgery lab featuring the latest advances in lateral single-position surgery (LSPS) and hosting a workshop focused on Anterior Lumbar Interbody Fusion (ALIF) and Transforaminal Lumbar Interbody Fusion (TLIF) procedural solutions.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SAN DIEGO, March 5, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will present at the Cowen and Company 39th Annual Health Care Conference at The Boston Marriott Copley Place in Boston on Tuesday, March 12, 2019, at 9:20 a.m. ET / 6:20 a.m. PT. A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. NuVasive, Inc. (NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes.
NuVasive, Inc. (NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings.
NuVasive (NUVA) delivered earnings and revenue surprises of 9.52% and 0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had net income of 23 cents. Earnings, adjusted for amortization costs and non-recurring costs, came to 69 cents per share. The results surpassed ...
Company provides 2019 financial performance guidance SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery ...
NEW YORK, NY / ACCESSWIRE / February 20, 2019 / NuVasive, Inc. (NASDAQ: NUVA ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 20, 2019 at 4:30 PM ...
SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) – as well as European CE mark approval – for use of its Precice® Bone Transport System, the only all-internal system of its kind on the market indicated for use in segmental bone loss treatment in the tibia and femur resulting from trauma or infection. The Precice Bone Transport System joins the NuVasive Specialized Orthopedics™ (NSO) family of advanced, magnetically adjustable limb-lengthening products which have collectively been used to treat thousands of patients.
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Shares of NuVasive, Inc. (NASDAQ: NUVA ) spiked after the Financial Times named the company as a potential acquisition target. A deal seems unlikely and, even if a bid is received, there is little opportunity ...
First reported by the Financial Times late Friday, NuVasive shares jumped as much as 18% on the Nasdaq Stock Exchange in after-hours trading. Citing "people with direct knowledge of the talks," the Financial Times noted that discussions between the companies were ongoing and that no definitive deal had been reached. London-based Smith & Nephew produces a wide range of medical equipment and products, including "advanced wound management products" and orthopedic reconstruction devices.
NuVasive stock popped Monday on a report Smith & Nephew could be considering buying it for about $3 billion. NuVasive stock made double-digit percentage gains in high volume on the news.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll look at NuVasive, Inc. (NASDAQ:NUVA)Read More...